Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s Association International Conference. The SHIMMER study showed significant improvement in behavioral outcomes, activities of daily living, cognitive fluctuations, and motor symptoms compared to placebo. These findings build upon earlier positive results from the SHINE study in Alzheimer’s disease, also showing zervimesine’s potential.
This development is critical because DLB, the second most common form of dementia, currently lacks disease-modifying treatments. The positive results observed across a range of DLB symptoms suggest zervimesine could address a significant unmet medical need, offering hope for patients and their families. Furthermore, the consistent positive signals observed in both DLB and Alzheimer’s diseaseAlzheimer’s disease studies strengthen the evidence for zervimesine’s broad neuroprotective mechanism, potentially targeting shared underlying pathologies.
The SHIMMER study, funded by the National Institutes of Health, involved 130 participants with mild-to-moderate DLB. Participants receiving zervimesine demonstrated an 86% improvement in behavioral outcomes, 52% in daily living activities, 91% in cognitive fluctuations, and 62% in motor symptoms compared to those receiving a placebo. These improvements were measured using established clinical scales such as the Neuropsychiatric Inventory and the Montreal Cognitive Assessment. Further details on clinical and biomarker effects, including findings related to p-Tau217 levels in the SHINE Alzheimer’s study, will be presented at the conference.
The positive Phase 2 results for zervimesine in DLB represent a major step forward for Cognition Therapeutics and potentially for the field of neurodegenerative disease research. The data suggest a promising therapeutic avenue for DLB and reinforce the potential of zervimesine as a disease-modifying treatment. While further research is needed, these findings could pave the way for future clinical trials and ultimately, a much-needed treatment option for this debilitating condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
